Drug intelligence / Profile preview

TC-NK

Development stage: Unknown
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TC-NK is a therapeutic cell product composed of purified natural killer (NK) cells. It is designed for use in haploidentical donor hematopoietic cell transplantation (HCT) for individuals diagnosed with high-risk hematologic malignancies. The product is derived from donor peripheral blood stem cells, which undergo G-CSF mobilization and apheresis collection, followed by purification to isolate the natural killer cells.

Other names: purified natural killer cells

Targets

FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))MAGEA8 (Melanoma-associated antigen 8)MICB (Major histocompatibility complex class i-related protein B)

Beyond the preview

Go deeper on TC-NK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TC-NK.

Explore the full profile